TABLE 1.
Baseline characteristics, impact on treatment management and outcome of COVID‐19 infection in 494 CLL patients by phase of the pandemic in Italy
| No. of patients (%) | |||||
|---|---|---|---|---|---|
| Question | Feb 2020–Jan 2021 | Phase 1(Feb–May 2020) (%) | Phase 2 (Jun–Sep 2020) (%) | Phase 3 (Oct 2020–Jan 2021) (%) | p |
| No. of COVID‐19+ CLL patients | 494 | 147 (29.7) | 28 (5.7) | 319 (64.6) | |
| Age at COVID‐19 infection | |||||
| <50 | 26 (5.3) | 3 (2.0) | 0 (0) | 23 (7.2) | 0.075 |
| 50‐65 | 144 (29.1) | 48 (32.7) | 12 (42.9) | 84 (26.3) | |
| 65‐75 | 171 (34.6) | 47 (32.0) | 10 (35.7) | 114 (35.8) | |
| >75 | 153 (31.0) | 49 (33.3) | 6 (21.4) | 98 (30.7) | |
| Treatment status at COVID‐19 infection | |||||
| Naïve | 236 (47.8) | 62 (42.2) | 17 (60.7) | 157 (49.2) | |
| Pre‐treated | 104 (21.0) | 37 (25.2) | 7 (25.0) | 60 (18.8) | 0.138 |
| On treatment | 154 (31.2) | 48 (32.6) | 4 (14.3) | 102 (32.0) | |
| Ongoing anti‐CLL treatment at the time of COVID‐19 infection | |||||
| CIT | 23 (15.0) | 6 (12.5) | 1 (25.0) | 16 (15.7) | |
| BTKi | 82 (53.2) | 22 (45.8) | 1 (25.0) | 59 (57.8) | 0.155 |
| PI3KD | 8 (5.2) | 4 (8.3) | 0 | 4 (3.9) | |
| V | 27 (17.5) | 14 (29.2) | 1 (25.0) | 12 (11.8) | |
| VR | 14 (9.1) | 2 (4.2) | 1 (25.0) | 11 (10.8) | |
| Anti‐CLL treatment withheld because of COVID‐19 infection (no. of patients/therapy) | |||||
| CIT | 22/23 (95.6) b | 6/6 | 1/1 | 15/16 | |
| BTKi | 44/82 (53.6) | 14/22 | 0/1 | 30/59 | |
| PI3KD | 7/8 (87.5) | 4/4 | 0 | 3/4 | 0.395 |
| V | 18/27 (66.6) | 10/14 | 1/1 | 7/12 | |
| VR | 10/14 (71.4) | 2/2 | 1/1 | 7/11 | |
| No. of COVID‐19+ CLL a | |||||
| Followed at home without O2 support | 187 (39.5) | 49 (33.8) | 17 (65.4) | 121 (39.9) | |
| Required non‐invasive O2 support | 192 (40.5) | 65 (44.8) | 6 (23.1) | 121 (39.9) | 0.053 |
| Required invasive O2 support | 95 (20.0) | 31 (21.4) | 3 (11.5) | 61 (20.2) | |
| No. of deaths/total no. of COVID‐19+ CLL | 122/494 (25) | 44/147 (29.9) | 5/28 (17.9) | 73/319 (22.9) | 0.180 |
Abbreviations: BTKi, Bruton tyrosine kinase inhibitors; CIT, chemoimmunotherapy; CLL, chronic lymphocytic leukemia; H, hospital; NA, not applicable; PI3KD, phosphatidylinositol‐3‐δ‐kinase; Tx, treatment; V, venetoclax; VR, venetoclax and rituximab.
a
Data available in 474 pts.
b
p = 0.003 for the probability to withhold therapy by treatment.